65,437 trials
Meibomian Gland Dysfunction · Dry Eye
Primary: Meibomian Glands Yielding Liquid Secretion (MGYLS) — -0.7; 3.41; 3.07; 1.88 Number of Open Glands
COVID-19 Pandemic
Primary: SARS-CoV-2 Testing — 54; 53; 123; 119 Participants — p=.944
Diabetes
Primary: Gestational Weight Gain — 7.9; 10.4 kg
Stroke
Primary: Change in Fugl-Meyer Assessment of the Upper Extremity — 5; 3.14 score on a scale
Musculoskeletal Pain
Primary: Change in Pain Assessment — 2.9; 4.0 score on a scale
Chronic Pain
Primary: The Proportion of Subjects With a Reduction in Overstimulation Sensation With SCS Using a Closed-loop Algorithm Compared With SCS in Open-loop — 41 Participants — p=<0.001
Bowel Cleansing
Primary: Incidence of Known Adverse Drug Reactions (ADRs) — 2; 1; 2; 6 Participants
Dermatomyositis · Idiopathic Inflammatory Myopathies
Primary: Change in Calcinosis Activity Visual Analogue Scale Score — -3.45 Units on a scale
Atopic Dermatitis
Primary: Time to Relapse (Quantile 25%) — 48; 15 Days
HIV/AIDS
Primary: HIV Testing Uptake — 68; 112 Participants — p=.01
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Endoscopic Ultrasound (EUS) · Endoscopic Retrograde Cholangiopancreatography (ERCP)
Primary: Average Percentage of Sedation Failures — 14; 13; 5 percentage of participants
Contraception
Primary: Maximum Observed Serum Concentration (Cmax) of Medroxyprogesterone Acetate (MPA) — 0.940; 1.180; 1.750; 0.963 nanograms (ng)/ milliliter (mL)
Breast Cancer
Primary: Time to Treatment Failure (TTF) Compared Between Treatment Groups. — 5.7; 8.3 months
Solid Tumors · Lymphoma
Primary: Part 1: Percentage of Participants Who Experienced a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 4.0 (CTCAE 4.0) — 15.1…